A Phase 1/2, Randomized, Sequential, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a One-Time, Bilateral, Intraparenchymal Infusion of SPK-10001 Into the Caudate and Putamen in Participants with Huntington's Disease
Latest Information Update: 03 Apr 2025
At a glance
- Drugs SPK 10001 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spark Therapeutics
- 26 Feb 2025 Status changed from not yet recruiting to recruiting.
- 21 Feb 2025 New trial record